Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
![UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA[®] (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease](/_up/ucb_com_presscenter/images/presscenter_teaser_5.jpg?300)
Twitter Feed
-
We officially welcome our new EVP and Chief Financial Officer Sandrine Dufour https://t.co/epocbiCUqH
— UCB News (@ucb_news) 08.07.2020 -
We’re excited to share our latest innovation in industry publication practices - Patient Publication Steering Committee. We presented this world-first, feasibility case study at the DIA Global Annual Meeting (June 2020). Access our poster/audio summaries:
— UCB News (@ucb_news) 08.07.2020 -
UCB is very proud to announce that the Swiss affiliate located in Bulle has obtained the Equal-Salary certification, symbol of excellence in terms of #equalpay. The site of Bulle is the first pharmaceutical company to be certified in Switzerland. https://
— UCB News (@ucb_news) 07.07.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
